Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02TNR
|
|||
| Former ID |
DNC006136
|
|||
| Drug Name |
N-(1-((cyanomethyl)carbamoyl)cyclohexyl)benzamide
|
|||
| Synonyms |
N-(1-((cyanomethyl)carbamoyl)cyclohexyl)benzamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H19N3O2
|
|||
| Canonical SMILES |
C1CCC(CC1)(C(=O)NCC#N)NC(=O)C2=CC=CC=C2
|
|||
| InChI |
1S/C16H19N3O2/c17-11-12-18-15(21)16(9-5-2-6-10-16)19-14(20)13-7-3-1-4-8-13/h1,3-4,7-8H,2,5-6,9-10,12H2,(H,18,21)(H,19,20)
|
|||
| InChIKey |
CSOZFSBRJJRGIA-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cathepsin K (CTSK) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Lysosome | |||
| Osteoclast differentiation | ||||
| Toll-like receptor signaling pathway | ||||
| Rheumatoid arthritis | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| RANKL Signaling Pathway | ||||
| IL2 Signaling Pathway | ||||
| Reactome | Collagen degradation | |||
| Degradation of the extracellular matrix | ||||
| Activation of Matrix Metalloproteinases | ||||
| Trafficking and processing of endosomal TLR | ||||
| MHC class II antigen presentation | ||||
| WikiPathways | RANKL/RANK Signaling Pathway | |||
| Osteoclast Signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Beta-substituted cyclohexanecarboxamide: a nonpeptidic framework for the design of potent inhibitors of cathepsin K. J Med Chem. 2006 Feb 9;49(3):1066-79. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.